With increasing attention in targeting aberrant Ras or its cooperative signaling for cancer treatment, our study provided the information for developing new therapeutic strategies that preferentially kill tumors with Nf1 defect at clinically achievable doses. The gene discussed is NF1; the disease is cancer.